Why the study?
Does the addition of azelnidipine compared to hydrochlorothiazide to olmesartan therapy improve central aortic pressure and arterial stiffness in hypertensive patients?
Population
207 hypertensive patients who received olmesartan monotherapy for 12 weeks prior to randomization.
Comparison
Azelnidipine added to olmesartan for 24 weeks. vs Hydrochlorothiazide added to olmesartan for 24…
Design
RCT, Randomized, Open-label, blinded end point
Follow-up
24 weeks
Authors
Loading...
Azelnidipine add-on to olmesartan yields superior central systolic BP reduction versus hydrochlorothiazide; extends evidence for CCB advantages on aortic hemodynamics.
Does the addition of azelnidipine compared to hydrochlorothiazide to olmesartan therapy improve central aortic pressure and arterial stiffness in hypertensive patients?
Adding azelnidipine to olmesartan reduces central systolic blood pressure and arterial stiffness more effectively than adding hydrochlorothiazide, despite similar reductions in brachial systolic blood pressure.
Matsui et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: